Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-09-03

FDA Approved: ORACEA — Supplemental Application (Galderma Laboratories, L.P.)

View source ↗

Summary

FDA approved a supplemental application for ORACEA (doxycycline) filed by Galderma Laboratories to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ORACEA (Doxycycline)

Snippet

SUPPL AP for ORACEA (DOXYCYCLINE)